

Sc(OTf)₃-Mediated [4 + 2] Annulations of *N*-Carbonyl Aryldiazenes with Cyclopentadiene to Construct Cinnoline Derivatives: Azo-Povarov Reaction

Xabier Jiménez-Aberásturi, Francisco Palacios, and Jesús M. de los Santos*



Cite This: *J. Org. Chem.* 2022, 87, 11583–11592



Read Online


ACCESS |

Metrics & More

Article Recommendations

Supporting Information

ABSTRACT: We disclose the first accomplishment of the azo-Povarov reaction involving Sc(OTf)₃-catalyzed [4 + 2] annulations of *N*-carbonyl aryldiazenes with cyclopentadiene in chloroform, in which *N*-carbonyl aryldiazenes act as 4π-electron donors. Hence, this protocol offers a rapid access to an array of cinnoline derivatives in moderate to good yields for substrates over a wide scope. The synthetic potential of the protocol was achieved by the gram-scale reaction and further derivatization of the obtained polycyclic product.



INTRODUCTION

The cinnoline ring is an important structural subunit found in a wide range of compounds of significant pharmacological and chemical importance.¹ Cinnoline derivatives display a broad spectrum of pharmacological activities, such as anticancer, antibacterial, antimicrobial, antifungal, anti-inflammatory, antimalarial, antiparasitic, and analgesic activity (Figure 1). For instance, Cinoxacin² is a synthetic antibiotic from the quinolone group used to treat urinary tract infections. On the other hand, some compounds with a cinnoline structure are found in preclinical tests, such as compound AZD7325,³ a modulator of GABA_A receptors that exhibits a powerful

anxiolytic effect (Figure 1). In particular, benzo[*c*]cinnolines are considered as important structures in medical chemistry due to the promising anticancer activities they possess. Several cinnoline derivatives such as dibenzo[*c,h*]cinnolines⁴ or indolo[3,2-*c*]cinnolines⁵ have been identified as potent anticancer agents and kinase inhibitors (Figure 1). In fact, the dibenzo[*c,h*]cinnolines are also topoisomerase I inhibitors and possess significant cytotoxic activity.⁴ The fact that none of these benzo[*c*]cinnolines is found in nature makes these skeletons highly interesting in organic synthesis.

However, traditional cinnoline access strategies such as intermolecular cycloaddition involving prefunctionalization of nitriles,⁶ aryl hydrazines,⁷ and aryl hydrazones,⁸ or cyclization of phenyldiazonium ions with highly active triazenes *ortho* to a terminal phenylacetylene,⁹ often involve a very limited synthetic scope and multi-stage reaction sequences and cannot represent a general synthetic method. The activation of the C–H bond catalyzed by transition metals is not only an important strategy in the synthesis and modification of heterocyclic systems,¹⁰ but also one of the most valuable methods for the preparation of the cinnoline backbone¹¹ due to the high degree of regioselectivity, atom economy, and reaction stages. For instance, in 2012, Ge et al.¹² developed a copper-promoted




Figure 1. Selected pharmaceutically and bioactive cinnoline derivatives.


Received: May 25, 2022

Published: August 16, 2022



intramolecular dehydrogenative cyclization of *N*-methyl-*N*-phenylhydrazones to afford cinnolines through C(sp³)H-oxidation, cyclization, and aromatization sequence (Scheme 1, eq 1). In 2016, Yao and Lin's group¹³ reported a rhodium-

Scheme 1. Transition Metal-Catalyzed Synthesis of Cinnolines



catalyzed redox-neutral annulation reaction between diazo and azo compounds for the preparation of cinnolines under mild conditions (Scheme 1, eq 2). Cinnolines have also been synthesized by Rh(III)-catalyzed C–H bond activation and cyclization of *N*-tert-butyl-aryldiazenes with alkynes (Scheme 1, eq 3).¹⁴

Furthermore, azo compounds, valuable synthetic building blocks, have been widely used in cycloaddition reactions with a variety of partners for the preparation of many nitrogen-containing heterocyclic compounds. For example, they have been widely used not only as dienophiles in azo hetero-Diels–Alder reactions^{15,16} [Scheme 2, eq 1)] but also as dienes in [4 + 2] cycloaddition reactions [Scheme 2, eq 2].¹⁷ Conjugated azoalkenes have proven to be valuable starting materials for the

synthesis of a plethora of multi-nitrogen-containing heterocycles and in target-oriented synthesis of naturally occurring and biologically active compounds.¹⁸ We have reported the usefulness of phosphorous-substituted azoalkenes for the preparation of α -amino phosphonates,¹⁹ functionalized mercapto diketones,²⁰ and heterocyclic compounds.^{21,22}

The classical Povarov reaction²³ between an aldimine, generated by the condensation of an aromatic amine and an aldehyde, and the olefinic or acetylenic component entails a useful tool for the construction of carbon–carbon and carbon–heteroatom bonds and the generation of six-membered rings with high molecular complexity. In this way, the Povarov reaction between imines and dienes is well known [Scheme 2, eq 3].²⁴ Our group has established the necessary methodology for the preparation and development of various TopI inhibitors with application as antiproliferative compounds using the Povarov reaction.²⁵ Very recently, an enantioselective gold-catalyzed [4 + 2]-annulation of nitrosoarenes and cyclopentadiene derivatives (nitroso-Povarov reaction) has been reported [Scheme 2, eq 4].²⁶

To continue our interest in new azoalkene reactions, as depicted in [Scheme 2, eq 5], herein, we report the first [4 + 2] annulation reaction (azo-Povarov reaction) between *N*-carbonyl aryldiazenes and cyclopentadiene, in which the *N*-carbonyl aryldiazene acts as the 4 π -electron (diene) system like *N*-arylimines in Povarov reactions.

RESULTS AND DISCUSSION

As outlined in Table 1, we started our investigation with the optimization of the reaction conditions with aryldiazene carboxylate **2a** as the model substrate and cyclopentadiene. Aryldiazene carboxylates are prepared by oxidation of aromatic hydrazine derivatives **1** using *N*-bromosuccinimide (NBS)/Py.²⁷ The effect of the catalyst on the azo-Povarov reaction was first evaluated with chloroform as the solvent. With ZnCl₂ as the catalyst, the reaction proceeded smoothly at room temperature to give the product **3a** in a 49% yield (entry 1). However, only a 9% yield of **3a** could be achieved when Ag(OTf) was used as the catalyst in this process (entry 2). Magnesium catalysts, such as MgBr₂·Et₂O and Mg(ClO₄)₂, are

Scheme 2. Annulations of Imines, Nitrosoarenes, and *N*-Carbonyl Aryldiazenes with Dienes





Table 1. Reaction Condition Optimization



entry ^a	catalyst	time (h)	T (° C)	solvent	yield (%) ^b
1	ZnCl ₂	5	rt	CHCl ₃	49
2	Ag(OTf)	4	rt	CHCl ₃	9
3	MgBr ₂ ·Et ₂ O	19	rt	CHCl ₃	0
4	Mg(ClO ₄) ₂	19	rt	CHCl ₃	0
5	MgBr ₂ ·Et ₂ O	48	55	CHCl ₃	0
6	Mg(ClO ₄) ₂	48	55	CHCl ₃	0
7	RuCl ₃	24	rt	CHCl ₃	0
8	MgBr ₂	24	rt	CHCl ₃	71
9	BF ₃ ·Et ₂ O	1	rt	CHCl ₃	39
10	Yb(OTf) ₃	6	rt	CHCl ₃	0
11	Sc(OTf) ₃	1	rt	CHCl ₃	91
12	Cu(OTf) ₂	3	rt	CHCl ₃	21
13	InCl ₃	2	rt	CHCl ₃	55
14	Sc(OTf) ₃	17	rt	THF	6
15	Sc(OTf) ₃	0.5	rt	DCM	87
16	Sc(OTf) ₃	1	rt	MeCN	57
17	Sc(OTf) ₃	0.5	rt	MeOH	0
18	Sc(OTf) ₃	24	rt	H ₂ O	0
19	Sc(OTf) ₃	15	50	H ₂ O	0
20	Sc(OTf) ₃	^c	rt	CHCl ₃	60


^aUnless otherwise noted, reactions were conducted on a 0.5 mmol scale, catalyst (1.5 equiv), and solvent (3 mL). ^bIsolated yields. ^cThe reaction was performed using 2a (0.5 mmol), catalyst (1.5 equiv), and solvent (1 mL) for 15 min.

not suitable for the current reaction since cinnoline 3a could not be detected, and only the starting aryldiazene carboxylate 2a was recovered instead (entries 3 and 4). A higher reaction temperature (55 °C) or longer reaction time (48 h) did not improve these results (entries 5 and 6). The use of RuCl₃ as the catalyst gave similar results (entry 7). To our surprise, since MgBr₂ afforded cinnoline 3a in 71% yield, BF₃·Et₂O, recently used by our group as the catalyst in the classical Povarov reaction,²⁵ only gave a 39% yield of 3a (entries 8 and 9). The use of Yb(OTf)₃ (entry 10) was also unsuitable for this transformation. After a series of optimization experiments, we identified Sc(OTf)₃ as the optimal catalyst. On performing the reaction at room temperature, product 3a was isolated in 91% yield after 1 h reaction time (entry 11). None of the other catalyst candidates that we explored (Cu(OTf)₂ or InCl₃) performed any better (entries 12 and 13). When examining the catalyst loading, the use of 1.5 equiv of catalyst seems necessary in the current reaction since we observed no reaction when different equivalents between 0.2 and 1.0 of Cu(OTf)₂, InCl₃, ZnCl₂, or Sc(OTf)₃ as Lewis acids were used.

The effect of the solvent on the azo-Povarov reaction was also studied. When performed with THF as the solvent, the reaction afforded traces of 3a (entry 14). In addition, using dichloromethane (DCM) as the solvent and lowering the reaction time to 0.5 h, led to similar results as before (compare entries 11 and 15). Starting aryldiazene carboxylate 2a was not fully consumed with MeCN (entry 16), whereas polar solvents such as MeOH (entry 17) and H₂O (entries 18 and 19) do not work in the azo-Povarov reaction. Finally, lowering the

reaction time to 15 min using chloroform as the solvent gave 3a with a moderate yield of 60% (entry 20).


With the optimal reaction conditions in hand, next we explored the substrate scope of the aromatic ring of aryl diazenes in the azo-Povarov reaction, and the results are summarized in Scheme 3. A large selection of functional

Scheme 3. Substrate Scope of the Aromatic Ring in Aryldiazene Carboxylates in the Azo-Povarov Reaction with Cyclopentadiene^a

^aSee the Supporting Information for experimental details.

groups at the aromatic ring in aryl diazenes 2 was well-tolerated. Both electron-donating (Me) and electron-withdrawing groups (Br, F, OCF₃, and CF₃) at the *para*-phenyl position afforded desired products 3c, 3b, 3d, 3e, and 3g in 24–77% yields. Among them, 4-bromo derivative 3b and 4-methyl derivative 3c were achieved with the best yields (77% and 65%, respectively). Nevertheless, *meta*-phenyl diazene 2f (R¹ = F, R² = H) afforded a 64:36 mixture of azo-Povarov adducts 3f and 3f' in 54% yield. The structure of 3a has been unambiguously determined by X-ray diffraction. The CIF data are presented in the Supporting Information, and the ORTEP drawing of 3a is shown in Scheme 3.

Stimulated by the above obtained results on the azo-Povarov reaction between aryl diazenes 2 and cyclopentadiene, we further investigated the substrate scope varying the functional group (R³) at the nitrogen atom of the aryl diazenes 2 (Scheme 4). To our delight, it was found that the reaction proceeded smoothly using the same reaction conditions, and starting aryl 2i or alkyl aryl diazenes 2h and 2j–2l afforded cinnoline derivatives 3i or 3h and 3j–3l, respectively. For instance, the Sc(OTf)₃-catalyzed [4 + 2] annulation reaction of phenyl aryl diazene carboxylate 2i (R³ = OPh) with cyclopentadiene afforded adduct 3i in 73% yield. *N*-Boc aryl diazene 2h (R³ = O^tBu) did not perform well since only 16% of cinnoline 3h was obtained. Nevertheless, annulations of other alkyl aryl diazenes 2j–2l bearing R³ = OBn (*N*-Cbz), Oallyl (*N*-Alloc), and 2,2,2-trichloroethoxy (*N*-Troc) moieties delivered cinnoline derivatives 3j–2l in 66–78% yields. Conversely, when *N*-acetyl

Scheme 4. Substrate Scope Varying Functional Group R³ at the Nitrogen Atom of *N*-Carbonyl Aryldiazenes^a

^aSee the Supporting Information for experimental details.


aryldiazene **2m** (R³ = Me) derived from *N'*-phenylacetohydrazide was used in the azo-Povarov reaction, a 59:41 mixture of regioisomers **3m** and **3m'** was observed in 92% yield. Similar results were attained with *p*-CF₃ phenyl diazene **2n**, and the corresponding adduct was obtained as a 74:26 regioisomeric mixture in 63% yield. Interestingly, only one regioisomer **3o** in almost quantitative yield has been observed when *N*-benzoyl aryldiazene **2o** (R³ = Ph) derived from *N'*-phenylbenzohydrazide was used in the current reaction. On comparing aryl and alkyl aryldiazene carboxylates **2h–l** with *N*-acyl or *N*-benzoyl aryldiazenes **2m–o**, better chemical yields were obtained for cinnolines derived from the latter (Scheme 4).

The gram-scale synthesis and further derivatization of **3a** have been accomplished, as shown in Scheme 5. The use of 3.0 mmol of aryldiazene carboxylate **2a** could give cinnoline derivative **3a** in 71% yield (0.523 g) under the standard conditions. In addition, transesterification of **3a** produced desired cinnoline **3p** in 73% yield in the presence of MeOH, and the reduction of the carbon–carbon double bond in **3a** was affected with hydrogenolysis using Ni/Raney as the catalyst affording product **4** in 97% yield.


A plausible mechanism for this Sc-catalyzed azo-Povarov reaction has been outlined in Scheme 6. Controversy exists about the mechanism of the Povarov reaction, suggesting a concerted mechanism²⁸ as well as evidences for a stepwise mechanism²⁹ have also arisen. Based on the stereochemistry of isolated compounds **3**, a mechanism with both *endo*- or *exo*- π -facial approach would explain the formation of these cinnolines **3**. Thus, the *endo*-facial approach of cyclopentadiene to **1** could lead to the [4 + 2] intermediate **6** and then the corresponding cycloadduct **3** (Scheme 6, approach from **5**, pathway i). However, the *exo*-facial approach of cyclopentadiene to **1** (Scheme 5, approach from **7**, pathway ii) would afford the

Scheme 5. Gram-Scale Synthesis and the Further Transformation of **3a**

a) Preparative-Scale reaction



b) Versatile Derivatization




same cinnoline **3** through intermediate cycloadduct **8**. Conversely, as observed previously for the Povarov reaction between aryl imines and 1,3-dienes,²⁹ a stepwise reaction mechanism through ionic intermediate **9** (Scheme 6, pathway iii) cannot be discarded.

CONCLUSIONS

In summary, we have developed a novel strategy to efficiently access the cinnoline scaffold from the [4 + 2] annulation reaction of *N*-carbonyl aryldiazenes and cyclopentadiene catalyzed by scandium triflate [Sc(OTf)₃]. This success represents the first example of the azo-Povarov reaction.

Scheme 6. Proposed Mechanism Pathways for the Azo-Povarov Reaction



Most of these [4 + 2]-annulations proceeded smoothly in chloroform for 1 h, giving exclusive regioselectivity and satisfactory yields. This protocol was applicable to a wide range of substrates, including various aryldiazenes with electron-donating (Me) and electron-withdrawing groups (Br, F, OCF₃, and CF₃) at the *para*-phenyl position and different aryldiazenes with reactive functional groups at the nitrogen atom. The synthetic potential of this azo-Povarov protocol was demonstrated with the preparative-scale reaction and versatile synthetic transformations of the product. This strategy for the preparation of the cinnoline backbone entails a valued method due to the atom economy, reaction stages, and high degree of regioselectivity. Further synthetic applications of this methodology are underway in our group and will be reported in due course.

EXPERIMENTAL SECTION

General Experimental Information. Solvents for extraction and chromatography were of technical grade. All solvents used in reactions were freshly distilled and dried over molecular sieves of 3 Å before use. All other solvents and reagents were obtained from commercial sources and recrystallized or distilled as necessary or used without further purification. All reactions were performed under an atmosphere of dry nitrogen. Melting points are uncorrected. IR spectra were measured on the Nicolet iS10 Thermo Fisher Scientific spectrometer as neat solids. Absorbance frequencies are given at the maximum intensity in cm⁻¹. High-resolution mass spectra (HRMS) were obtained by the positive-ion electrospray ionization (ESI) method with a time-of-flight Q-TOF system. Data are reported in the form of *m/z* (intensity relative to base = 100). ¹H (300, 400 MHz), ¹³C (75, 100 MHz), and ¹⁹F (282, 376 MHz) spectra were recorded on Varian Unity Plus (300 MHz) or Bruker Avance 400 (400 MHz) spectrometers, respectively, in CDCl₃, as specified below. Chemical shifts (δ_H) are reported in parts per million (ppm) with the internal chloroform signal at 7.24 ppm as the standard for ¹H NMR. Chemical shifts (δ_C and δ_F) are reported in parts per million (ppm) with the internal chloroform signal at 77.0 ppm for ¹³C NMR and the external trichlorofluoromethane (Cl₃CF) signal at 0.0 ppm as the standard for ¹⁹F NMR. All coupling constant (*J*) values are given in Hz. ¹⁹F and ¹³C NMR spectra were recorded in a broad band decoupling mode from hydrogen nuclei. Distortionless enhanced polarization transfer

supported peak assignments for ¹³C NMR. The data is being reported as (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = double doublet, bs = broad singlet). Chromatographic purification was performed as flash chromatography using commercial grades of silica gel finer than 230 mesh with pressure or neutral aluminum oxide. Analytical thin layer chromatography (TLC) was performed on precoated Merck silica gel 60 F₂₅₄ TLC aluminum plates, and spot visualized with UV light or permanganate stain. Functionalized hydrazines **1h** and **1m** are commercially available. However, functionalized hydrazines **1a**,³⁰ **1b**,^{30,31} **1c**,³⁰ **1d**,³⁰ **1f**,^{30,31} **1g**,³⁰ **1i**,^{30,32} **1j**,^{30,31} **1k**,^{30,33} **1l**,^{30,31} **1n**,^{34,35} and **1o**³⁴ and *N*-carbonyl aryldiazenes **2a**,³⁰ **2b**,^{30,31} **2c**,³⁰ **2d**,³⁰ **2f**,^{30,31} **2g**,³⁰ **2h**,^{30,31} **2i**,^{30,32} **2j**,^{30,31} **2k**,^{30,33} **2l**,^{30,31} **2m**,^{30,36} and **2o**^{30,31} were prepared according to literature procedures.

Experimental Procedure and Characterization Data for Compounds 1–2. *General Procedure and Spectral Data for Functionalized Hydrazines 1.* To a 0 °C stirred solution of the corresponding hydrazine hydrochloride (15 mmol) in CH₃CN (30 mL) and pyridine (2.5 mL, 31.5 mmol), ethyl chloroformate (1.6 mL, 16.5 mmol) was added dropwise. The reaction mixture was stirred for 15 min at 0 °C and then for 3 h at room temperature. Water (30 mL) was added and the resulting mixture was acidified with HCl (6 M) to pH 4–6. The crude product was extracted with CH₂Cl₂ (5 × 15 mL). The combined organic layers were washed with saturated aqueous NaHCO₃ (15 mL) and brine (15 mL), dried over anhydrous MgSO₄, filtered, and concentrated to dryness in a vacuum. The crude product was purified by recrystallization from an appropriate solvent, as indicated in the literature procedure,³⁰ to afford functionalized hydrazines **1**.

Ethyl 2-(4-(trifluoromethoxy)phenyl)hydrazine-1-carboxylate (1e). Following the literature procedure,³⁰ **1e** was obtained as a brown solid (80% yield). mp: 89–91 °C; IR (neat) ν_{max} 3102, 3048, 2991, 1712, 1682 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.04 (d, *J* = 8.8 Hz, 2H), 6.78 (bs, 1H), 6.74 (d, *J* = 8.8 Hz, 2H), 6.07 (bs, 1H), 4.16 (q, *J* = 7.1 Hz, 2H), 1.29–1.19 (m, 3H); ¹³C {¹H} NMR (75 MHz, CDCl₃) δ (ppm): 157.3, 146.7, 142.9 (q, ³J_{CF} = 1.7 Hz), 122.2, 120.5 (q, ¹J_{CF} = 254.3 Hz), 113.5, 62.1, 14.4; ¹⁹F NMR (282 MHz, CDCl₃) δ (ppm): -58.8. ESI-HRMS (CI) *m/z*: calcd for C₁₀H₁₂F₃N₂O₃ ([M + H]⁺), 265.0800; found, 265.0804.

General Procedure and Spectral Data for N-Carbonyl Aryldiazenes 2. To a stirred solution of the corresponding functionalized hydrazines **1** (3 mmol) in CH₂Cl₂ (21 mL), pyridine (0.68 mL, 8.4 mmol) was added. Then, NBS (599 mg, 3.30 mmol) was added

portionwise. The reaction mixture was stirred for 30 min and then washed with aqueous HCl (5%, 30 mL), aqueous sodium thiosulfate (1.5%, 15 mL), saturated aqueous NaHCO₃ (30 mL), and brine (30 mL). The organic layer was dried over anhydrous MgSO₄, filtered, and concentrated to dryness in a vacuum to give pure aryl and alkyl diazene carboxylates **2**, as indicated in the literature procedure.³⁰

Ethyl 2-(4-(trifluoromethoxy)phenyl)diazene-1-carboxylate (2e). Following the literature procedure,³⁰ **2e** was obtained as a red oil (95% yield) and was used immediately without purification in the next reaction step. IR (neat) ν_{\max} 3081, 2987, 2940, 1761 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ (ppm): 7.94 (d, *J* = 8.9 Hz, 2H), 7.31 (d, *J* = 8.9 Hz, 2H), 4.48 (q, *J* = 7.1 Hz, 2H), 1.42 (t, *J* = 7.1 Hz, 3H); ¹³C {¹H} NMR (75 MHz, CDCl₃) δ (ppm): 161.8, 152.9 (q, ³*J*_{CF} = 1.7 Hz), 149.4, 125.4, 121.0 (q, ⁴*J*_{CF} = 0.8 Hz), 120.2 (q, ¹*J*_{CF} = 257.7 Hz), 64.5, 14.0; ¹⁹F NMR (282 MHz, CDCl₃) δ (ppm): -58.2.

1-((4-(Trifluoromethyl)phenyl)diazene)ethan-1-one (2n). Following the literature procedure,³⁰ **2n** was obtained as a red oil (<99%) and was used immediately without purification in the next reaction step. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.94 (d, *J* = 8.7 Hz, 2H), 7.77 (d, *J* = 8.7 Hz, 2H), 2.42 (s, 3H); ¹³C {¹H} NMR (75 MHz, CDCl₃) δ (ppm): 188.1, 153.0, 134.4 (q, ²*J*_{CF} = 32.8 Hz), 126.6 (q, ³*J*_{CF} = 3.7 Hz), 123.6, 123.4 (q, ¹*J*_{CF} = 273.7 Hz), 21.2; ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): -62.9.

Experimental Procedure and Characterization Data for Functionalized Cinnolines 3. To a stirred solution of the corresponding *N*-carbonyl aryl diazene **2** (0.5 mmol, 1 equiv) in CHCl₃ (3 mL), was added cyclopentadiene (63 μ L, 0.75 mmol, 1.5 equiv) and Sc(OTf)₃ (373 mg, 0.75 mmol, 1.5 equiv) under a nitrogen atmosphere. The reaction mixture was stirred at room temperature for 1–6 h, and then, it was diluted with CH₂Cl₂ (40 mL) and washed with NaOH (2 M, 50 mL) and water (2 \times 50 mL). The organic layers were dried over anhydrous MgSO₄, filtered, and concentrated to dryness in a vacuum. The crude product was purified by recrystallization in hexane at -24 °C or by column chromatography to afford the corresponding cinnoline derivatives **3**.

Ethyl (3*aR,9*bR**)-3,3*a*,5,9*b*-tetrahydro-4*H*-cyclopenta[*c*]cinnoline-4-carboxylate (3a).** (111 mg, 91%) as a black solid from aryl diazene carboxylate **2a** (99 mg, 0.5 mmol) was obtained after 1 h reaction, as described in the general procedure. The crude product was purified by flash-column chromatography (SiO₂, hexanes/AcOEt 98:2) to afford the title compound **3a**. mp: 97–99 °C; IR (neat) ν_{\max} 3058, 2982, 2930, 1694 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.07 (dq, *J* = 7.6, 0.6 Hz, 1H), 7.03 (tdd, *J* = 7.6, 1.5, 0.6 Hz, 1H), 6.88 (td, *J* = 7.6, 1.4 Hz, 1H), 6.79 (d, *J* = 7.6 Hz, 1H), 6.33 (bs, 1H), 5.75 (dq, *J* = 6.0, 2.2 Hz, 1H), 5.63 (dq, *J* = 6.0, 2.2 Hz, 1H), 5.35 (q, *J* = 8.7 Hz, 1H), 4.16 (q, *J* = 7.1 Hz, 2H), 4.02 (dq, *J* = 8.7, 2.2 Hz, 1H), 2.83–2.68 (m, 2H), 1.24 (t, *J* = 7.1 Hz, 3H); ¹³C {¹H} NMR (75 MHz, CDCl₃) δ (ppm): 155.3, 144.7, 132.5, 129.8, 128.7, 126.6, 126.2, 122.0, 115.2, 62.2, 55.8, 44.7, 36.1, 14.5; ESI-HRMS (CI) *m/z*: calcd for C₁₄H₁₇N₂O₂ ([M + H]⁺), 245.1290; found, 245.1285.

Ethyl (3*aR,9*bR**)-8-bromo-3,3*a*,5,9*b*-tetrahydro-4*H*-cyclopenta[*c*]cinnoline-4-carboxylate (3b).** (125 mg, 77%) as a black solid from aryl diazene carboxylate **2b** (161 mg, 0.5 mmol) was obtained after 1.5 h reaction, as described in the general procedure. The crude product was purified by flash-column chromatography (SiO₂, hexanes/AcOEt 98:2) to afford the title compound **3b**. mp: 114–116 °C; IR (neat) ν_{\max} 3062, 2964, 2927, 1644 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.20 (d, *J* = 2.2 Hz, 1H), 7.13 (dd, *J* = 8.4, 2.2 Hz, 1H), 6.67 (d, *J* = 8.4 Hz, 1H), 6.23 (bs, 1H), 5.76 (dq, *J* = 6.1, 2.4 Hz, 1H), 5.60 (dq, *J* = 6.1, 2.3 Hz, 1H), 5.32 (q, *J* = 6.6 Hz, 1H), 4.15 (q, *J* = 7.1 Hz, 2H, OCH₂), 3.96 (d, *J* = 8.9 Hz, 1H) 2.76–2.71 (m, 2H), 1.24 (t, *J* = 7.1 Hz, 3H); ¹³C {¹H} NMR (75 MHz, CDCl₃) δ (ppm): 155.4, 143.8, 131.8, 131.3, 130.3, 129.0, 128.8, 116.8, 114.0, 62.3, 55.6, 44.5, 35.9, 14.4; ESI-HRMS (CI) *m/z*: calcd for C₁₄H₁₆BrN₂O₂ ([M + H]⁺), 323.0395; found, 323.0399.

Ethyl (3*aR,9*bR**)-8-methyl-3,3*a*,5,9*b*-tetrahydro-4*H*-cyclopenta[*c*]cinnoline-4-carboxylate (3c).** (84 mg, 65%) as a brown solid from aryl diazene carboxylate **2c** (101 mg, 0.5 mmol) was obtained after 1.5 h reaction, as described in the general procedure. The crude product was purified by flash-column

chromatography (SiO₂, hexanes/AcOEt 98:2) to afford the title compound **3c**. mp: 60–62 °C; IR (neat) ν_{\max} 3331, 3054, 2924, 1694 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ (ppm): 6.90 (t, *J* = 1.6 Hz, 1H), 6.84 (dd, *J* = 8.0, 1.6 Hz, 1H), 6.70 (d, *J* = 8.0 Hz, 1H), 6.21 (bs, 1H), 5.74 (dq, *J* = 6.0, 2.3 Hz, 1H), 5.63 (dq, *J* = 6.0, 2.4 Hz, 1H), 5.33 (q, *J* = 5.2 Hz, 1H), 4.15 (q, *J* = 7.1 Hz, 2H), 3.97 (dd, *J* = 9.3, 2.4 Hz, 1H), 2.82–2.64 (m, 2H), 2.24 (s, 3H), 1.24 (t, *J* = 7.1 Hz, 3H); ¹³C {¹H} NMR (100 MHz, CDCl₃) δ (ppm): 155.4, 142.2, 132.6, 131.5, 129.7, 129.4, 126.8, 115.3, 62.2, 55.7, 44.8, 36.1, 20.7, 14.5; ESI-HRMS (CI) *m/z*: calcd for C₁₅H₁₉N₂O₂ ([M + H]⁺), 259.1447; found, 259.1451.

Ethyl (3*aR,9*bR**)-8-fluoro-3,3*a*,5,9*b*-tetrahydro-4*H*-cyclopenta[*c*]cinnoline-4-carboxylate (3d).** (54 mg, 41%) as a black solid from aryl diazene carboxylate **2d** (109 mg, 0.5 mmol) was obtained after 3 h reaction, as described in the general procedure. The crude product was purified by flash-column chromatography (SiO₂, hexanes/AcOEt 98:2) to afford the title compound **3d**. mp: 91–94 °C; IR (neat) ν_{\max} 3061, 2925, 1694 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ (ppm): 6.81–6.78 (m, 1H), 6.75–6.72 (m, 2H), 6.15 (bs, 1H), 5.77 (dq, *J* = 6.1, 2.3 Hz, 1H), 5.59 (dq, *J* = 6.1, 2.3 Hz, 1H), 5.31 (q, *J* = 7.2 Hz, 1H), 4.15 (q, *J* = 7.1 Hz, 2H), 3.97 (dt, *J* = 9.2, 2.3 Hz, 1H), 2.76–2.72 (m, 2H), 1.23 (t, *J* = 7.1 Hz, 3H); ¹³C {¹H} NMR (75 MHz, CDCl₃) δ (ppm): 158.2 (d, ¹*J*_{CF} = 240.2 Hz), 156.6, 140.9 (d, ⁴*J*_{CF} = 2.5 Hz), 131.8, 130.4, 128.7, 116.6 (d, ³*J*_{CF} = 8.0 Hz), 115.2 (d, ²*J*_{CF} = 22.4 Hz), 112.9 (d, ²*J*_{CF} = 22.8 Hz), 62.4, 55.4, 45.1, 36.2, 14.5; ¹⁹F NMR (282 MHz, CDCl₃) δ (ppm): -121.7. ESI-HRMS (CI) *m/z*: calcd for C₁₄H₁₆FN₂O₂ ([M + H]⁺), 263.1196; found, 263.1198.

Ethyl (3*aR,9*bR**)-8-(trifluoromethoxy)-3,3*a*,5,9*b*-tetrahydro-4*H*-cyclopenta[*c*]cinnoline-4-carboxylate (3e).** (83 mg, 51%) as a black solid from aryl diazene carboxylate **2e** (131 mg, 0.5 mmol) was obtained after 6 h reaction, as described in the general procedure. The crude product was purified by flash-column chromatography (SiO₂, hexanes/AcOEt 98:2) to afford the title compound **3e**. mp: 69–71 °C; IR (neat) ν_{\max} 3324, 3088, 2985, 2933, 1694 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ (ppm): 6.94 (d, *J* = 2.3 Hz, 1H), 6.91–6.87 (m, 1H), 6.78 (d, *J* = 8.5 Hz, 1H), 6.30 (bs, 1H), 5.77 (dq, *J* = 6.1, 2.3 Hz, 1H), 5.60 (dq, *J* = 6.1, 2.3 Hz, 1H), 5.33 (q, *J* = 7.2 Hz, 1H), 4.16 (q, *J* = 7.1 Hz, 2H), 3.99 (d, *J* = 9.1 Hz, 1H), 2.81–2.68 (m, 2H), 1.24 (t, *J* = 7.1 Hz, 3H); ¹³C {¹H} NMR (75 MHz, CDCl₃) δ (ppm): 155.4, 143.7 (q, ³*J*_{CF} = 2.1 Hz), 143.5, 131.8, 130.5, 128.2, 121.7, 120.5 (q, ¹*J*_{CF} = 256.1 Hz, CF₃), 119.3 (C2), 116.1, 62.5, 55.5, 44.8, 36.1, 14.5; ¹⁹F NMR (282 MHz, CDCl₃) δ (ppm): -58.6. ESI-HRMS (CI) *m/z*: calcd for C₁₅H₁₆F₃N₂O₃ ([M + H]⁺), 329.1113; found, 329.1123.

Ethyl (3*aR,9*bR**)-7-fluoro-3,3*a*,5,9*b*-tetrahydro-4*H*-cyclopenta[*c*]cinnoline-4-carboxylate (3f) and Ethyl (3*aR**,9*bR**)-9-fluoro-3,3*a*,5,9*b*-tetrahydro-4*H*-cyclopenta[*c*]cinnoline-4-carboxylate (3f').** (71 mg, 54%) as a brown solid from aryl diazene carboxylate **2f** (117 mg, 0.5 mmol) was obtained after 1 h reaction, as described in the general procedure. The crude product was purified by flash-column chromatography (SiO₂, hexanes/AcOEt 98:2) to afford the title compound **3f/3f'** as a mixture in a ratio of 64:36. mp: 86–88 °C; IR (neat) ν_{\max} 3067, 2982, 2930, 1682, 1620 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.01–6.95 (m, 2H, H₉^{major}, H₇^{minor}), 6.61–6.55 (m, 3H, H₆^{major}, H₆^{minor}, H₈^{minor}), 6.51 (d, *J* = 9.5 Hz, 1H, H₈^{major}), 6.31 (bs, 2H, H₅^{major}, H₅^{minor}), 5.79–5.74 (m, 2H, H₂^{major}, H₂^{minor}), 5.73–5.72 (m, 1H, H₁^{minor}), 5.61–5.58 (m, 1H, H₁^{major}), 5.40–5.30 (m, 2H, H_{3a}^{major}, H_{3a}^{minor}), 4.19–4.13 (m, 4H, OCH₂^{major}, OCH₂^{minor}), 4.11 (bs, 1H, H_{9b}^{minor}), 3.97 (d, *J* = 9.5 Hz, 1H, H_{9b}^{major}), 2.85–2.79 (m, 2H, H₃^{minor}), 2.79–2.65 (m, 2H, H₃^{major}), 1.27–1.23 (m, 6H, CH₃^{major}, CH₃^{minor}); ¹³C {¹H} NMR (100 MHz, CDCl₃) δ (ppm): 161.1 (d, ¹*J*_{CF} = 245.43 Hz, C₉^{minor}), 161.0 (d, ¹*J*_{CF} = 244.9 Hz, C₇^{major}), 155.4 (C=O)^{minor}, 155.4 (C=O)^{major}, 146.1 (d, ³*J*_{CF} = 8.2 Hz, C_{5a}^{minor}), 146.0 (d, ³*J*_{CF} = 9.1 Hz, C_{5a}^{major}), 132.4 (C₁^{major}), 131.0 (d, ⁴*J*_{CF} = 1.9 Hz, C₁^{minor}), 130.1 (C₂^{minor}), 130.0 (d, ³*J*_{CF} = 9.1 Hz, C₉^{major}), 129.9 (C₂^{major}), 127.1 (d, ³*J*_{CF} = 9.8 Hz, C₇^{minor}), 122.3 (C_{9a}^{major}), 114.3 (d, ²*J*_{CF} = 20.2 Hz, C_{9a}^{minor}), 110.6 (d, ⁴*J*_{CF} = 3.0 Hz, C₆^{minor}), 108.8 (d, ²*J*_{CF} = 21.6 Hz, C₈^{major}), 108.2 (d, ²*J*_{CF} = 21.8 Hz, C₈^{minor}), 102.4 (d, ²*J*_{CF} = 24.6 Hz, C₆^{major}), 62.4 (OCH₂^{major+minor}), 55.8 (C_{3a}^{major}), 55.5 (C_{3a}^{minor}), 44.2 (C_{9b}^{major}), 39.3 (C_{9b}^{minor}), 36.0 (CH₂^{major}), 35.3 (CH₂^{minor}), 14.5

(CH₃major+minor); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): -115.7_{major} -117.9_{minor}; ESI-HRMS (CI) *m/z*: calcd for C₁₄H₁₆FN₂O₂ ([M + H]⁺), 263.1196; found, 263.1171.

Ethyl (3*aR,9*bR**)-8-(trifluoromethyl)-3,3*a*,5,9*b*-tetrahydro-4*H*-cyclopenta[*c*]cinnoline-4-carboxylate (3*g*).** (38 mg, 24%) as a brown solid from aryldiazene carboxylate **2g** (123 mg, 0.5 mmol) was obtained after 2.5 h reaction, as described in the general procedure. The crude product was purified by flash-column chromatography (Al₂O₃, hexanes/AcOEt 95:5) to afford the title compound **3g**. mp: 61–63 °C; IR (neat) ν_{\max} 3064, 2987, 2931, 1682, 1619 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.31–7.30 (m, 1H), 7.29–7.26 (m, 1H), 6.83 (d, *J* = 8.2 Hz, 1H), 6.45 (bs, 1H), 5.77 (dq, *J* = 6.0, 1.9 Hz, 1H), 5.63 (dq, *J* = 6.0, 1.9 Hz, 1H), 5.37 (q, *J* = 6.8 Hz, 1H), 4.17 (q, *J* = 7.1 Hz, 2H), 4.03 (dd, *J* = 9.2, 1.9 Hz, 1H), 2.82–2.68 (m, 2H), 1.25 (t, *J* = 7.1 Hz, 3H); ¹³C {¹H} NMR (100 MHz, CDCl₃) δ (ppm): 155.3, 147.7, 131.9, 130.5, 126.7, 126.0 (q, ³*J*_{CF} = 3.5 Hz), 124.3 (q, ¹*J*_{CF} = 272.7 Hz), 123.8 (q, ²*J*_{CF} = 33.3 Hz), 123.6 (q, ³*J*_{CF} = 3.8 Hz), 114.9, 62.6, 55.9, 44.5, 35.9, 14.6; ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): -61.7. ESI-HRMS (CI) *m/z*: calcd for C₁₅H₁₆F₃N₂O₂ ([M + H]⁺), 313.1164; found, 313.1171.

tert-Butyl (3*aR,9*bR**)-3,3*a*,5,9*b*-tetrahydro-4*H*-cyclopenta[*c*]cinnoline-4-carboxylate (3*h*).** (30 mg, 16%) as a brown oil from aryldiazene carboxylate **2h** (103 mg, 0.5 mmol) was obtained after 1 h reaction, as described in the general procedure. The crude product was purified by flash-column chromatography (Al₂O₃, hexanes/AcOEt 97:3) to afford the title compound **3h**. IR (neat) ν_{\max} 3056, 2998, 2925, 2866, 1964 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.07 (d, *J* = 7.5 Hz, 1H), 7.04–7.00 (m, 1H), 6.86 (td, *J* = 7.5, 1.2 Hz, 1H), 6.77 (d, *J* = 7.9 Hz, 1H), 6.27 (bs, 1H), 5.74 (dq, *J* = 6.0, 2.2 Hz, 1H), 5.63–5.60 (m, 1H), 5.28 (q, *J* = 5.8 Hz, 1H), 4.00 (dd, *J* = 9.2, 1.8 Hz, 1H), 2.81–2.67 (m, 2H), 1.41 (s, 9H); ¹³C {¹H} NMR (100 MHz, CDCl₃) δ (ppm): 154.9, 145.1, 132.6, 129.9, 128.8, 126.8, 126.2, 121.9, 115.1, 81.3, 55.9, 44.8, 36.3, 28.3; ESI-HRMS (CI) *m/z*: calcd for C₁₂H₁₃N₂O₂ ([M - 'Bu + 2H]⁺), 217.0977; found, 217.0970.

Phenyl (3*aR,9*bR**)-3,3*a*,5,9*b*-tetrahydro-4*H*-cyclopenta[*c*]cinnoline-4-carboxylate (3*i*).** (106 mg, 73%) as a white powder from aryldiazene carboxylate **2i** (119 mg, 0.5 mmol) was obtained after 1 h reaction, as described in the general procedure. The crude product was purified by recrystallization in hexane at -24 °C to afford the title compound **3i**. mp: 113–116 °C; IR (neat) ν_{\max} 3327, 3061, 2936, 1690 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.33 (t, *J* = 7.6 Hz, 2H), 7.19 (tt, *J* = 7.6, 1.1 Hz, 1H), 7.13 (d, *J* = 7.5 Hz, 1H), 7.12 (dt, *J* = 7.6, 1.1 Hz, 2H), 6.94 (t, *J* = 7.5 Hz, 1H), 6.88 (d, *J* = 7.7, 1.0 Hz, 1H), 6.48 (bs, 1H), 5.80 (dq, *J* = 6.0, 2.2 Hz, 1H), 5.68 (dq, *J* = 6.0, 2.3 Hz, 1H), 5.50 (qd, *J* = 9.3 Hz, 1.4 Hz, 1H), 4.14 (d, *J* = 9.3 Hz, 1H), 2.93–2.79 (m, 2H); ¹³C {¹H} NMR (100 MHz, CDCl₃) δ (ppm): 153.0, 151.0, 144.4, 132.5, 129.8, 129.3, 128.8, 126.5, 126.3, 125.6, 122.5, 121.5, 115.5, 56.4, 45.2, 36.5 (CH₂); ESI-HRMS (CI) *m/z*: calcd for C₁₈H₁₇N₂O₂ ([M + H]⁺), 293.1290; found, 293.1282.

Benzyl (3*aR,9*bR**)-3,3*a*,5,9*b*-tetrahydro-4*H*-cyclopenta[*c*]cinnoline-4-carboxylate (3*j*).** (120 mg, 78%) as a white powder from aryldiazene carboxylate **2j** (133 mg, 0.5 mmol) was obtained after 1 h reaction, as described in the general procedure. The crude product was purified by recrystallization in hexane at -24 °C to afford the title compound **3j**. mp: 108–110 °C; IR (neat) ν_{\max} 3296, 3059, 2944, 1694 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.36–7.28 (m, 5H), 7.08 (d, *J* = 7.5 Hz, 1H), 7.04 (td, *J* = 7.5, 1.4 Hz, 1H), 6.89 (td, *J* = 7.5, 1.2 Hz, 1H), 6.78 (d, *J* = 7.5 Hz, 1H), 6.35 (bs, 1H), 5.74 (dq, *J* = 6.1, 2.3 Hz, 1H), 5.62 (dq, *J* = 6.1, 2.3 Hz, 1H), 5.37 (bs, 1H), 5.13 (s, 2H), 4.02 (d, *J* = 9.3 Hz, 1H), 2.80 (ddq, *J* = 17.0, 6.4, 2.3 Hz, 1H), 2.75–2.68 (m, 1H); ¹³C {¹H} NMR (100 MHz, CDCl₃) δ (ppm): 155.2, 144.7, 136.0, 132.5, 129.7, 128.7, 128.5, 128.1, 127.9, 126.6, 126.3, 122.2, 115.3, 67.9, 56.0, 44.9, 36.2; ESI-HRMS (CI) *m/z*: calcd for C₁₉H₁₉N₂O₂ ([M + H]⁺), 307.1447; found, 307.1439.

Allyl (3*aR,9*bR**)-3,3*a*,5,9*b*-tetrahydro-4*H*-cyclopenta[*c*]cinnoline-4-carboxylate (3*k*).** (84 mg, 66%) as a brown oil from aryldiazene carboxylate **2k** (102 mg, 0.5 mmol) was obtained after 1 h reaction, as described in the general procedure. The crude product

was purified by flash-column chromatography (Al₂O₃, hexanes/AcOEt 95:5) to afford the title compound **3k**. IR (neat) ν_{\max} 3059, 3018, 2988, 1964 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.08 (d, *J* = 7.5 Hz, 1H), 7.06–7.02 (m, 1H), 6.89 (td, *J* = 7.5, 1.2 Hz, 1H), 6.79 (d, *J* = 7.7 Hz, 1H), 6.34 (bs, 1H), 5.90 (ddt, *J* = 16.8, 10.6, 5.5 Hz, 1H), 5.75 (dq, *J* = 6.0, 2.1 Hz, 1H), 5.64 (dq, *J* = 6.0, 2.1 Hz, 1H), 5.38 (q, *J* = 9.1 Hz, 1H), 5.26 (d, *J* = 16.8 Hz, 1H), 5.24 (d, *J* = 10.6 Hz, 1H), 4.61 (dt, *J* = 5.5, 1.4 Hz, 2H), 4.04 (dd, *J* = 9.1, 2.1 Hz, 1H), 2.81 (ddq, *J* = 17.2, 6.8, 2.3 Hz, 1H), 2.75–2.69 (m, 1H); ¹³C {¹H} NMR (100 MHz, CDCl₃) δ (ppm): 154.9, 144.6, 132.5, 132.3, 129.7, 128.7, 126.6, 126.3, 122.1, 117.8, 115.3, 66.7, 55.9, 44.8, 36.1; ESI-HRMS (CI) *m/z*: calcd for C₁₅H₁₇N₂O₂ ([M + H]⁺), 257.1290; found, 257.1264.

2,2,2-Trichloroethyl (3*aR,9*bR**)-3,3*a*,5,9*b*-tetrahydro-4*H*-cyclopenta[*c*]cinnoline-4-carboxylate (3*l*).** (115 mg, 66%) as a white powder from aryldiazene carboxylate **2l** (141 mg, 0.5 mmol) was obtained after 1 h reaction, as described in the general procedure. The crude product was purified by recrystallization in hexane at -24 °C to afford the title compound **3l**. mp: 91–93 °C; IR (neat) ν_{\max} 3315, 3063, 3004, 2956, 2916, 1694 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.09 (d, *J* = 7.6 Hz, 1H), 7.05 (t, *J* = 7.6 Hz, 1H), 6.91 (td, *J* = 7.6, 1.0 Hz, 1H), 6.84–6.80 (m, 1H), 6.39 (bs, 1H), 5.77 (dq, *J* = 5.9, 2.2 Hz, 1H), 5.64–5.62 (m, 1H), 5.41 (q, *J* = 8.6 Hz, 1H), 4.81 (d, *J* = 10.8 Hz, 1H), 4.72 (d, *J* = 10.8 Hz, 1H), 4.08 (d, *J* = 8.6 Hz, 1H), 2.88–2.75 (m, 2H, CH₂); ¹³C {¹H} NMR (100 MHz, CDCl₃) δ (ppm): 153.1, 144.3, 132.4, 129.7, 129.0, 128.7, 126.5, 122.5, 115.5, 95.2, 75.4, 56.5, 45.2, 36.4; ESI-HRMS (CI) *m/z*: calcd for C₁₄H₁₄Cl₃N₂O₂ ([M + H]⁺), 347.0121; found, 347.0111.

(3*aR,9*bR**)-1-(3,3*a*,5,9*b*-Tetrahydro-4*H*-cyclopenta[*c*]cinnolin-4-yl)ethan-1-one (3*m*) and (3*aR**,9*bR**)-1-(1,3*a*,5,9*b*-Tetrahydro-4*H*-cyclopenta[*c*]cinnolin-4-yl)ethan-1-one (3*m*').** (99 mg, 92%) as a brown solid from *N*-acetyl aryldiazene **2m** (74 mg, 0.5 mmol) was obtained after 1.5 h reaction, as described in the general procedure. The crude product was purified by recrystallization in hexane at -24 °C to afford the title compound **3m/3m'** as a mixture of regioisomers in a ratio of 59:41. mp: 57–60 °C; IR (neat) ν_{\max} 3067, 2923, 2850, 1634 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.70 (bs, 1H, H₅major), 7.12–7.10 (m, 2H, H₇minor, H₉minor), 7.08–7.01 (m, 3H, H₇major, H₉major, H₈minor), 6.95 (d, *J* = 7.9 Hz, 1H, H₆minor), 6.86 (td, *J* = 7.5, 1.2 Hz, 1H, H₈major), 6.80 (dd, *J* = 7.9, 1.2 Hz, 1H, H₆major), 5.77–5.71 (m, 4H, H₂major, H₂minor, H₃minor, H_{3a}minor), 5.68 (dq, *J* = 6.0, 2.4 Hz, 1H, H₁major), 5.51 (bs, 1H, H₅minor), 5.04 (qd, *J* = 9.2, 1.4 Hz, 1H, H_{3a}major), 4.09 (dd, *J* = 9.2, 2.1 Hz, 1H, H_{9b}major), 4.00 (d, *J* = 9.2 Hz, 1H, H_{9b}minor), 2.84 (ddq, *J* = 16.8, 6.5, 2.4 Hz, 1H, H₃major), 2.75–2.65 (m, 2H, H₃major, H₁minor), 2.46–2.39 (m, 1H, H₁minor), 2.20 (s, 3H, CH₃minor), 2.17 (s, 3H, CH₃major); ¹³C {¹H} NMR (100 MHz, CDCl₃) δ (ppm): 172.9 (C=O)minor, 163.4 (C=O)major, 143.8 (C_{5a}major), 141.6 (C_{5a}minor), 133.1 (C₃)minor, 132.5 (C₁major), 130.4 (C_{9a}minor), 129.8 (C₂minor), 129.3 (C₂major), 128.8 (C₉minor), 128.4 (C₇major), 126.7 (C₉major), 126.6 (C₇minor), 125.4 (C_{9a}major), 124.9 (C₈minor), 121.9 (C₈major), 121.1 (C₆minor), 115.1 (C₆major), 57.3 (C_{3a}major), 52.2 (C_{3a}minor), 45.4 (C_{9b}major), 44.2 (C_{9b}minor), 36.5 (C₃major), 34.7 (C₁minor), 21.5 (CH₃minor), 20.2 (CH₃major); ESI-HRMS (CI) *m/z*: calcd for C₁₃H₁₅N₂O ([M + H]⁺), 215.1184; found, 215.1184.

(3*aR,9*bR**)-1-(8-(Trifluoromethyl)-3,3*a*,5,9*b*-tetrahydro-4*H*-cyclopenta[*c*]cinnolin-4-yl)ethan-1-one (3*n*) and (3*aR**,9*bR**)-1-(8-(Trifluoromethyl)-1,3*a*,5,9*b*-tetrahydro-4*H*-cyclopenta[*c*]cinnolin-4-yl)ethan-1-one (3*n*').** (125 mg, 63%) as a white powder from *N*-acetyl aryldiazene **2n** (152 mg, 0.7 mmol), cyclopentadiene (73 μL, 0.87 mmol), and Sc(OTf)₃ (378 mg, 0.77 mmol) was obtained after 1.5 h reaction, as described in the general procedure. The crude product was purified by recrystallization in hexane at -24 °C to afford the title compound **3n/3n'** as a mixture of regioisomers in a ratio of 74:26. mp: 128–134 °C; IR (neat) ν_{\max} 3060, 3058, 2920, 2850, 1634 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.87 (bs, 1H, H₅major), 7.36–7.34 (m, 2H, H₇minor, H₉minor), 7.31–7.28 (m, 2H, H₇major, H₉major), 7.01 (d, *J* = 8.6 Hz, 1H, H₆minor), 6.86 (d, *J* = 8.1 Hz, 1H, H₆major), 5.82–5.75 (m, 3H, H₂major, H₂minor, H₃minor), 5.71 (dq, *J* = 6.0, 2.3 Hz, 1H, H₁major), 5.65 (bs, 2H, H_{3a}minor, H₅minor), 5.09 (td, *J* = 7.5, 1.2 Hz, 1H, H₈major), 5.04 (qd, *J* = 9.2, 1.4 Hz, 1H, H_{3a}major), 4.09 (dd, *J* = 9.2, 2.1 Hz, 1H, H_{9b}major), 4.00 (d, *J* = 9.2 Hz, 1H, H_{9b}minor), 2.84 (ddq, *J* = 16.8, 6.5, 2.4 Hz, 1H, H₃major), 2.75–2.65 (m, 2H, H₃major, H₁minor), 2.46–2.39 (m, 1H, H₁minor), 2.20 (s, 3H, CH₃minor), 2.17 (s, 3H, CH₃major); ¹³C {¹H} NMR (100 MHz, CDCl₃) δ (ppm): 172.9 (C=O)minor, 163.4 (C=O)major, 143.8 (C_{5a}major), 141.6 (C_{5a}minor), 133.1 (C₃)minor, 132.5 (C₁major), 130.4 (C_{9a}minor), 129.8 (C₂minor), 129.3 (C₂major), 128.8 (C₉minor), 128.4 (C₇major), 126.7 (C₉major), 126.6 (C₇minor), 125.4 (C_{9a}major), 124.9 (C₈minor), 121.9 (C₈major), 121.1 (C₆minor), 115.1 (C₆major), 57.3 (C_{3a}major), 52.2 (C_{3a}minor), 45.4 (C_{9b}major), 44.2 (C_{9b}minor), 36.5 (C₃major), 34.7 (C₁minor), 21.5 (CH₃minor), 20.2 (CH₃major); ESI-HRMS (CI) *m/z*: calcd for C₁₃H₁₅N₂O ([M + H]⁺), 215.1184; found, 215.1184.

$J = 8.9, 6.8, 1.7$ Hz, 1H, H3a_{major}), 4.11 (dd, $J = 8.9, 2.3$ Hz, 1H, H9b_{major}), 4.02 (d, $J = 8.9$ Hz, 1H, H9b_{minor}), 2.83 (ddq, $J = 16.9, 6.8, 2.3$ Hz, 1H, C3_{major}), 2.72 (ddt, $J = 16.9, 8.9, 2.3$ Hz, 1H, C3_{major}), 2.44 (dd, $J = 7.8, 2.1$ Hz, 1H, C1_{minor}), 2.40 (dd, $J = 7.8, 1.8$ Hz, 1H, C1_{minor}), 2.20 (s, 6H, CH_{3major}, CH_{3minor}); ¹³C {¹H} NMR (100 MHz, CDCl₃) δ (ppm): 172.8 (C=O)_{minor}, 163.6 (C=O)_{major}, 146.4 (q, ⁵J_{CF} = 1.1 Hz, C5a_{major}), 144.4 (C5a_{minor}), 132.4 (C3_{minor}), 131.8 (C1_{major}), 130.3 (C2_{minor}), 130.0 (C2_{major}), 129.7 (C9a_{minor}), 126.2 (q, ³J_{CF} = 3.9 Hz, C9_{minor}), 126.2 (q, ²J_{CF} = 32.3 Hz, C8_{minor}), 125.6 (q, ³J_{CF} = 3.8 Hz, C9_{major}), 125.3 (C9a_{major}), 124.3 (q, ¹J_{CF} = 271.7 Hz, CF_{3major}), 124.1 (q, ¹J_{CF} = 272.7 Hz, CF_{3minor}), 123.8 (q, ³J_{CF} = 3.8 Hz, C7_{major}), 123.6 (q, ³J_{CF} = 3.7 Hz, C7_{minor}), 123.6 (q, ²J_{CF} = 32.3 Hz, C8_{major}), 120.0 (C6_{minor}), 114.8 (C6_{major}), 57.2 (C3a_{major}), 52.0 (C3a_{minor}), 45.0 (C9b_{major}), 43.7 (C9b_{minor}), 36.1 (C3_{major}), 33.7 (C1_{minor}), 21.5 (CH_{3minor}), 20.0 (CH_{3major}); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): -61.7_{major}, -62.0_{minor}; ESI-HRMS (CI) m/z : calcd for C₁₄H₁₄F₃N₂O ([M + H]⁺), 283.1058; found, 283.1033.

Phenyl((3aR*,9bR*)-3,3a,5,9b-tetrahydro-4H-cyclopenta[c]-cinnolin-4-yl)methanone (3o). (138 mg, >99%) as a brown solid from *N*-benzoyl aryldiazene 2o (108 mg, 0.5 mmol) was obtained after 1 h reaction, as described in the general procedure. The crude product was purified by recrystallization in hexane at -24 °C to afford the title compound 3o. mp: 53–56 °C; IR (neat) ν_{\max} 3286, 3057, 2922, 1628 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.71 (bs, 1H), 7.48–7.41 (m, 5H), 7.11–7.06 (m, 2H), 6.92–6.89 (m, 2H), 5.72–5.66 (m, 2H), 5.05–4.99 (m, 1H), 3.97 (d, $J = 8.3$ Hz, 1H), 3.02 (d, $J = 11.9$ Hz, 1H), 2.67–2.61 (m, 1H); ¹³C {¹H} NMR (100 MHz, CDCl₃) δ (ppm): 165.2, 143.8, 134.4, 132.5, 130.2, 129.3, 128.6, 128.5, 127.1, 126.7, 125.6, 122.0, 115.3, 58.3, 45.1, 36.6; ESI-HRMS (CI) m/z : calcd for C₁₈H₁₇N₂O ([M + H]⁺), 277.1341; found, 277.1336.

Gram Scale Procedure of Cinnoline 3a. To a stirred solution of aryldiazene carboxylate 2a (535 mg, 3 mmol) in CHCl₃ (9 mL), was added cyclopentadiene (0.38 mL, 4.5 mmol, 1.5 equiv) and Sc(OTf)₃ (2.237 g, 4.5 mmol, 1.5 equiv) under a nitrogen atmosphere. The reaction mixture was stirred at room temperature for 1–6 h, and then, it was diluted with CH₂Cl₂ (40 mL) and washed with NaOH (2 M, 50 mL) and water (2 × 50 mL). The organic layers were dried over anhydrous MgSO₄, filtered, and concentrated to dryness in vacuum. The crude product was purified by column chromatography to afford the desired cinnoline 3a (523 mg, 71% yield).

Synthetic Transformations. Synthesis of Compound 3p. A stirred solution of 3a (0.2 mmol, 49 mg) in MeOH (3 mL) was refluxed using a heating mantle for 48 h under a nitrogen atmosphere. Then, the crude reaction was diluted with H₂O (25 mL), and the product was extracted with CH₂Cl₂ (2 × 25 mL). The organic layers were dried over anhydrous MgSO₄, filtered, and concentrated to dryness in a vacuum. The crude product was purified by flash-column chromatography (SiO₂, hexanes/AcOEt 97:3) to afford the title compound 3p.

Methyl (3aR*,9bR*)-3,3a,5,9b-tetrahydro-4H-cyclopenta[c]-cinnoline-4-carboxylate (3p). Brown solid, 34 mg, 73%; mp: 86–89 °C; IR (neat) ν_{\max} 3058, 2956, 2924, 1694 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.07 (dt, $J = 7.5, 0.7$ Hz, 1H), 7.06–7.01 (m, 1H), 6.89 (td, $J = 7.5, 1.2$ Hz, 1H), 6.79 (d, $J = 7.9$ Hz, 1H), 6.16 (bs, 1H), 5.74 (dq, $J = 6.0, 2.3$ Hz, 1H), 5.62 (dq, $J = 6.0, 2.3$ Hz, 1H), 5.33 (s, 1H), 4.01 (d, $J = 9.2$ Hz, 1H), 3.72 (s, 3H), 2.82–2.67 (m, 2H); ¹³C {¹H} NMR (100 MHz, CDCl₃) δ (ppm): 155.7, 144.6, 132.5, 129.8, 128.8, 126.7, 126.4, 122.3, 115.4, 55.9, 53.3, 44.8, 36.2; ESI-HRMS (CI) m/z : calcd for C₁₃H₁₅N₂O₂ ([M + H]⁺), 231.1134; found, 231.1126.

Synthesis of Compound 4. To a stirred solution of 3a (0.2 mmol, 49 mg) in MeOH (10 mL), Ni-Raney (~50 mg, washed with MeOH) was added, and the reaction mixture was stirred under a hydrogen atmosphere (2 bar) for 22 h. Then, the crude product was filtered through a pad of Celite to obtain the pure title compound 4.

Ethyl (3aR*,9bR*)-1,2,3,3a,5,9b-hexahydro-4H-cyclopenta[c]-cinnoline-4-carboxylate (4). Brown oil, 48 mg, 97%; IR (neat) ν_{\max} 3327, 3061, 2956, 2867, 1694 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.08 (d, $J = 7.5$ Hz, 1H), 7.03 (t, $J = 7.3$ Hz, 1H), 6.88 (t, $J =$

7.4, Hz, 1H), 6.78 (d, $J = 7.8$ Hz, 1H), 6.27 (bs, 1H), 4.87 (q, $J = 8.1$ Hz, 1H), 4.14 (q, $J = 7.1$ Hz, 2H), 3.26 (q, $J = 8.1$ Hz, 1H), 2.10–1.97 (m, 2H), 1.95–1.88 (m, 1H), 1.74–1.65 (m, 1H), 1.64–1.57 (m, 1H), 1.53–1.44 (m, 1H), 1.24 (t, $J = 7.1$ Hz, 3H); ¹³C {¹H} NMR (75 MHz, CDCl₃) δ (ppm): 155.0, 144.5, 128.9, 128.7, 125.9, 121.8, 114.7, 62.0, 57.1, 38.2, 34.8, 29.2, 23.7, 14.5; ESI-HRMS (CI) m/z : calcd for C₁₄H₁₉N₂O₂ ([M + H]⁺), 247.1447; found, 247.1437.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acs.joc.2c01224>.

General experimental procedures; characterization data; NMR and ESI-HRMS spectra of 1e, 2e, 2n, 3, and 4; and crystallographic structure of 3a (PDF)

Accession Codes

CCDC 2164540 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, or by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033.

■ AUTHOR INFORMATION

Corresponding Author

Jesús M. de los Santos – Department of Organic Chemistry I, Faculty of Pharmacy and Lascaray Research Center, University of the Basque Country (UPV/EHU), Vitoria 01006, Spain; orcid.org/0000-0003-1315-4263; Email: jesus.delossantos@ehu.es

Authors

Xabier Jiménez-Aberásturi – Department of Organic Chemistry I, Faculty of Pharmacy and Lascaray Research Center, University of the Basque Country (UPV/EHU), Vitoria 01006, Spain

Francisco Palacios – Department of Organic Chemistry I, Faculty of Pharmacy and Lascaray Research Center, University of the Basque Country (UPV/EHU), Vitoria 01006, Spain

Complete contact information is available at:

<https://pubs.acs.org/doi/10.1021/acs.joc.2c01224>

Notes

The authors declare no competing financial interest.

CCDC 2164540 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, or by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033.

■ ACKNOWLEDGMENTS

Financial support by the Ministerio de Ciencia, Innovación y Universidades (MCIU), Agencia Estatal de Investigación (AEI) y Fondo Europeo de Desarrollo Regional (FEDER) (RTI2018-101818-B-I00, UE), and Gobierno Vasco (GV, IT 992-16) is gratefully acknowledged. X.J.-A. thanks the Basque Country Government for the granted pre-doctoral fellowship. The authors thank technical and human support provided by SGiker (UPV/EHU/ERDF, EU).

REFERENCES

- (1) For reviews on cinnoline derivatives with biological activity, see: (a) Szumilak, M.; Stanczak, A. Cinnoline Scaffold-A Molecular Heart of Medicinal Chemistry? *Molecules* **2019**, *24*, 2271. (b) Lewgowd, W.; Stanczak, A. Cinnoline derivatives with biological activity. *Arch. Pharm.* **2007**, *340*, 65–80.
- (2) Cinobac. Available online: <https://www.rxlist.com/cinobac-drug.htm#clinpharm> (accessed July 11, 2022).
- (3) te Beek, E. T.; Chen, X.; Jacobs, G. E.; Nahon, K. J.; de Kam, M. L.; Cross, J.; van Gerven, A. J.; Hay, J. M. A.; Hay, J. L. The effects of the nonselective benzodiazepine lorazepam and the $\alpha 2/\alpha 3$ subunit-selective GABA_A receptor modulators AZD7325 and AZD6280 on plasma prolactin levels. *Clin. Pharmacol. Drug Dev.* **2015**, *4*, 149–154.
- (4) Yu, Y.; Singh, S. K.; Liu, A.; Li, T.-K.; Liu, L. F.; LaVoie, E. J. Substituted dibenzo[*c,h*]cinnolines: topoisomerase I-targeting anticancer agents. *Bioorg. Med. Chem.* **2003**, *11*, 1475–1491.
- (5) Barraja, P.; Diana, P.; Lauria, A.; Passannanti, A.; Almerico, A. M.; Minnei, C.; Longu, S.; Congiu, D.; Musiu, C.; La Colla, P. Indolo[3,2-*c*]cinnolines with antiproliferative, antifungal, and antibacterial activity. *Bioorg. Med. Chem.* **1999**, *7*, 1591–1596.
- (6) Alhambra, C.; Becker, C.; Blake, T.; Chang, A. H.-F.; Daniels, J. R., Jr.; Dembofsky, T.; Gurley, B. T.; Hall, D. A.; Herzog, J. E.; Horchler, K. J.; Ohnmacht, C. L.; Schmieging, C. J.; Dudley, R. J.; Ribadeneira, A.; Knappenberger, M. D.; Maciag, K. S.; Stein, C.; Chopra, M. M.; Liu, M.; Christian, X. F.; Arriza, E. P.; Chapdelaine, J. L.; Chapdelaine, M. Development and SAR of functionally selective allosteric modulators of GABA_A receptors. *Bioorg. Med. Chem.* **2011**, *19*, 2927–2938.
- (7) Jurberg, I. D.; Gagosz, F. Formation of cinnoline derivatives by a gold(I)-catalyzed hydroarylation of N-propargyl-N'-arylhydrazines. *J. Organomet. Chem.* **2011**, *696*, 37–41.
- (8) (a) Gomaa, M. A.-M. An efficient and facile synthesis of substituted cinnoline and benzo[*h*]cinnoline derivatives. *Tetrahedron Lett.* **2003**, *44*, 3493–3496. (b) Shvartsberg, M. S.; Ivanchikova, I. D. An unknown route of cyclocondensation of *peri*-acetylenylquinones with hydrazine. *Tetrahedron Lett.* **2000**, *41*, 771–773. (c) Kiselyov, A. S.; Dominguez, C. A novel synthesis of 3,4-disubstituted cinnolines from *o*-trifluorophenyl hydrazones. *Tetrahedron Lett.* **1999**, *40*, 5111–5114. (d) Kanner, C. B.; Pandit, U. K. Reaction of β -amino- α,β -unsaturated esters and amides with aryl diazonium salts. *Tetrahedron* **1981**, *37*, 3513–3518.
- (9) Kimball, D. B.; Hayes, A. G.; Haley, M. M. Thermal cyclization of (2-ethynylphenyl)triazenes: facile synthesis of substituted cinnolines and isoindazoles. *Org. Lett.* **2000**, *2*, 3825–3827.
- (10) For reviews on C–H bond activation for the synthesis of heterocycles, see: (a) Nie, B.; Wu, W.; Zhang, Y.; Jiang, H.; Zhang, J. Recent advances in the synthesis of bridgehead (or ring-junction) nitrogen heterocycles via transition metal-catalyzed C–H bond activation and functionalization. *Org. Chem. Front.* **2020**, *7*, 3067–3099. (b) Baccalini, A.; Fata, G.; Zanon, G.; Maiti, D. Transition Metal Promoted Cascade Heterocycle Synthesis through C–H Functionalization. *Chem.—Eur. J.* **2020**, *26*, 9749–9783. (c) Nguyen, T. H. L.; Gigant, N.; Joseph, D. Advances in direct metal-catalyzed functionalization of azobenzenes. *ACS Catal.* **2018**, *8*, 1546–1579.
- (11) (a) Zhang, X.; Bai, R.; Xiong, H.; Xu, H.; Hou, W. Meeting organometallic chemistry with drug discovery: C–H activation enabled discovery of a new ring system of 12H-Indazolo[2,1-*a*]cinnolin-12-ones with anti-proliferation activity. *Bioorg. Med. Chem. Lett.* **2020**, *30*, 126916. (b) Liu, C.-F.; Liu, M.; Dong, L. Iridium(III)-Catalyzed Tandem Annulation Synthesis of Pyrazolo[1,2- α]cinnolines from Pyrazolones and Sulfoxonium Ylides. *J. Org. Chem.* **2019**, *84*, 409–416.
- (12) Zhang, G.; Miao, J.; Zhao, Y.; Ge, H. Copper-catalyzed aerobic dehydrogenative cyclization of *N*-methyl-*N*-phenylhydrazones: synthesis of cinnolines. *Angew. Chem., Int. Ed.* **2012**, *51*, 8318–8321.
- (13) Sun, P.; Wu, Y.; Huang, Y.; Wu, X.; Xu, J.; Yao, H.; Lin, A. Rh(III)-catalyzed redox-neutral annulation of azo and diazo compounds: one-step access to cinnolines. *Org. Chem. Front.* **2016**, *3*, 91–95.
- (14) Zhao, D.; Wu, Q.; Huang, X.; Song, F.; Lv, T.; You, J. A general method to diverse cinnolines and cinnolinium salts. *Chem.—Eur. J.* **2013**, *19*, 6239–6244.
- (15) For reviews on azo hetero-Diels–Alder using azo compounds as dienophiles, see: (a) Maeorg, U.; Tsupova, S. Hydrazines and azo-compounds in the synthesis of heterocycles comprising N–N bond. *Heterocycles* **2014**, *88*, 129–173. (b) Yamamoto, H.; Kawasaki, M. Nitroso and azo compounds in modern organic synthesis: late blooming but very rich. *Bull. Chem. Soc. Jpn.* **2007**, *80*, 595–607. (c) Tietze, L. F.; Ketschau, G. Hetero Diels–Alder reactions in organic chemistry. *Top. Curr. Chem.* **1997**, *189*, 1–120.
- (16) For contributions on the asymmetric azo hetero-Diels–Alder using azo compounds as dienophiles (a) Momiyama, N.; Tabuse, H.; Noda, H.; Yamanaka, M.; Fujimami, T.; Yamanishi, K.; Izumiseki, A.; Funayama, K.; Egawa, F.; Okada, S.; Adachi, H.; Terada, M. Molecular Design of a Chiral Brønsted Acid with Two Different Acidic Sites: Regio-, Diastereo-, and Enantioselective Hetero-Diels–Alder Reaction of Azopyridinecarboxylate with Amidodienes Catalyzed by Chiral Carboxylic Acid-Monophosphoric Acid. *J. Am. Chem. Soc.* **2016**, *138*, 11353–11359. (b) Liu, B.; Liu, T.-Y.; Luo, S.-W.; Gong, L.-Z. Asymmetric Hetero-Diels–Alder Reaction of Diazenes Catalyzed by Chiral Silver Phosphate: Water Participates in the Catalysis and Stereocontrol. *Org. Lett.* **2014**, *16*, 6164–6167. (c) Kawasaki, M.; Yamamoto, H. Catalytic Enantioselective Hetero-Diels–Alder Reactions of an Azo Compound. *J. Am. Chem. Soc.* **2006**, *128*, 16482–16483.
- (17) For contributions on azo hetero-Diels–Alder using azo compounds as dienes, see: (a) Yang, X.-L.; Peng, X.-X.; Chen, F.; Han, B. TEMPO-Mediated Aza-Diels–Alder Reaction: Synthesis of Tetrahydropyridazines Using Ketohydrazones and Olefins. *Org. Lett.* **2016**, *18*, 2070–2073. (b) Tong, M.-C.; Chen, X.; Li, J.; Huang, R.; Tao, H.; Wang, C.-J. Catalytic Asymmetric Synthesis of [2,3]-Fused Indoline Heterocycles through Inverse-Electron-Demand Aza-Diels–Alder Reaction of Indoles with Azoalkenes. *Angew. Chem., Int. Ed.* **2014**, *53*, 4680–4684.
- (18) For contributions on azoalkenes as synthetic intermediates, see: (a) Wei, L.; Shen, C.; Hu, Y.-Z.; Tao, H.-Y.; Wang, C.-J. Enantioselective synthesis of multi-nitrogen-containing heterocycles using azoalkenes as key intermediates. *Chem. Commun.* **2019**, *55*, 6672–6684. (b) Lopes, S. M. M.; Cardoso, A. L.; Lemos, A.; Pinho e Melo, T. M. V. D. Recent advances in the chemistry of conjugated nitrosoalkenes and azoalkenes. *Chem. Rev.* **2018**, *118*, 11324–11352. (c) Attanasi, O. A.; Favi, G.; Mantellini, F.; Moscatelli, G.; Santeusano, S. A novel assembly of substituted pyrroles by acid-catalyzed sequential three-component reaction of amines, alkynoates, and 1,2-diaza-1,3-dienes. *Adv. Synth. Catal.* **2011**, *353*, 1519–1524. (d) Attanasi, O. A.; Favi, G.; Filippone, P.; Mantellini, F.; Moscatelli, G.; Perrulli, F. R. Copper(II)/Copper(I)-Catalyzed Aza-Michael Addition/Click Reaction of in Situ Generated α -Azidohydrazones: Synthesis of Novel Pyrazolone–Triazole Framework. *Org. Lett.* **2010**, *12*, 468–471. (e) Attanasi, O. A.; De Crescentini, L.; Favi, G.; Filippone, P.; Mantellini, F.; Perrulli, F. R.; Santeusano, S. Cultivating the Passion to Build Heterocycles from 1,2-Diaza-1,3-dienes: the Force of Imagination. *Eur. J. Org. Chem.* **2009**, *2009*, 3109–3127.
- (19) (a) Palacios, F.; Aparicio, D.; López, Y.; de los Santos, J. M. Synthesis of functionalized α -amino-phosphine oxides and -phosphonates by addition of amines and aminoesters to 4-phosphinyl- and 4-phosphonyl-1,2-diaza-1,3-butadienes. *Tetrahedron* **2005**, *61*, 2815–2830. (b) Palacios, F.; Aparicio, D.; López, Y.; de los Santos, J. M. Addition of amine derivatives to phosphorylated 1,2-diaza-1,3-butadienes. Synthesis of α -aminophosphonates. *Tetrahedron Lett.* **2004**, *45*, 4345–4348.
- (20) Attanasi, O. A.; Lillini, S.; Mantellini, F.; de los Santos, J. M.; Ignacio, R.; Palacios, F. Domino reaction for the construction of new 2-oxo[1,2,4]triazolo [5,1-*c*][1,4]thiazines. *Synlett* **2009**, *2009*, 735–738.
- (21) Palacios, F.; Aparicio, D.; López, Y.; de los Santos, J. M.; Alonso, C. Cycloaddition Reactions of Phosphorylated 1,2-Diaza-1,3-

butadienes with Olefins: Regioselective Synthesis of Pyridazine Derivatives. *Eur. J. Org. Chem.* **2005**, 2005, 1142–1147.

(22) Aparicio, D.; Attanasi, O. A.; Filippone, P.; Ignacio, R.; Lillini, S.; Mantellini, F.; Palacios, F.; de los Santos, J. M. Straightforward access to pyrazines, piperazinones, and quinoxalines by reactions of 1,2-diaza-1,3-butadienes with 1,2-diamines under solution, solvent-free, or solid-phase conditions. *J. Org. Chem.* **2006**, *71*, 5897–5905.

(23) (a) Ren, X.-R.; Bai, B.; Zhang, Q.; Hao, L.-J.; Guo, D.; Wan, Q.; Wang, Y. Constructing stable chromenoquinoline-based covalent organic frameworks via intramolecular Povarov reaction. *J. Am. Chem. Soc.* **2022**, *144*, 2488–2494. (b) Umerani, M. J.; Yang, H.; Pratakshya, P.; Nowick, J. S.; Gorodetsky, A. A. An aza-Diels-Alder route to quinoline-based unnatural amino acids and polypeptide surrogates. *RSC Adv.* **2021**, *11*, 14132–14139. (c) Shi, F.; Xing, G.-J.; Tao, Z.-L.; Luo, S.-W.; Tu, S.-J.; Gong, L.-Z. An asymmetric organocatalytic Povarov reaction with 2-hydroxystyrenes. *J. Org. Chem.* **2012**, *77*, 6970–6979. (d) Bello, D.; Ramon, R.; Lavilla, R. Mechanistic variations of the Povarov multicomponent reaction and related processes. *Curr. Org. Chem.* **2010**, *14*, 332–356. (e) Legros, J.; Crousse, B.; Ourévitche, M.; Bonnet-Delpon, D. Facile Synthesis of Tetrahydroquinolines and Julolidines through -Multicomponent Reaction. *Synlett* **2006**, 2006, 1899–1902. (f) Twin, H.; Batey, R. A. Intramolecular Hetero Diels–Alder (Povarov) Approach to the Synthesis of the Alkaloids Luotonin A and Camptothecin. *Org. Lett.* **2004**, *6*, 4913–4916. (g) Ishitani, H.; Kobayashi, S. Catalytic asymmetric aza Diels–Alder reactions using a chiral lanthanide Lewis acid. Enantioselective synthesis of tetrahydroquinoline derivatives using a catalytic amount of a chiral source. *Tetrahedron Lett.* **1996**, *37*, 7357–7360. (h) McCarrick, M. A.; Wu, Y. D.; Houk, K. N. Hetero-Diels–Alder reaction transition structures: reactivity, stereoselectivity, catalysis, solvent effects, and the exo-lone-pair effect. *J. Org. Chem.* **1993**, *58*, 3330–3343. (i) Povarov, L. S. $\alpha\beta$ -UNSATURATED ETHERS AND THEIR ANALOGUES IN REACTIONS OF DIENE SYNTHESIS. *Russ. Chem. Rev.* **1967**, *36*, 656–670.

(24) (a) Goli, N.; Kallepu, S.; Mainkar, P. S.; Lakshmi, J. K.; Chegondi, R.; Chandrasekhar, S. Synthetic strategy toward the pentacyclic core of Melodinus alkaloids. *J. Org. Chem.* **2018**, *83*, 2244–2249. (b) Imrich, H.-G.; Conrad, J.; Bubrin, D.; Beifuss, U. From nitrobenzenes to substituted tetrahydroquinolines in a single step by a domino reduction/imine formation/aza-Diels–Alder reaction. *J. Org. Chem.* **2015**, *80*, 2319–2332.

(25) (a) Martín-Encinas, E.; Rubiales, G.; Knudsen, B. R.; Palacios, F.; Alonso, C. Fused chromeno and quinolino[1,8]naphthyridines: Synthesis and biological evaluation as topoisomerase I inhibitors and antiproliferative agents. *Bioorg. Med. Chem.* **2021**, *40*, 116177. (b) Martín-Encinas, E.; Selas, A.; Tesauro, C.; Rubiales, G.; Knudsen, B. R.; Palacios, F.; Alonso, C. Synthesis of novel hybrid quinolino[4,3-*b*][1,5]naphthyridines and quinolino[4,3-*b*][1,5]-naphthyridin-6(5*H*)-one derivatives and biological evaluation as topoisomerase I inhibitors and antiproliferatives. *Eur. J. Med. Chem.* **2020**, *195*, 112292. (c) Martín-Encinas, E.; Rubiales, G.; Knudsen, B. R.; Palacios, F.; Alonso, C. Straightforward synthesis and biological evaluation as topoisomerase I inhibitors and antiproliferative agents of hybrid chromeno[4,3-*b*][1,5]naphthyridines and chromeno[4,3-*b*]-[1,5]naphthyridin-6-ones. *Eur. J. Med. Chem.* **2019**, *178*, 752–766. (d) Tejería, A.; Pérez-Pertejo, Y.; Reguera, R. M.; Carbajo-Andrés, R.; Balaña-Fouce, R.; Alonso, C.; Martín-Encinas, E.; Selas, A.; Rubiales, G.; Palacios, F. Antileishmanial activity of new hybrid tetrahydroquinoline and quinoline derivatives with phosphorus substituents. *Eur. J. Med. Chem.* **2019**, *162*, 18–31. (e) Alonso, C.; Fuertes, M.; Martín-Encinas, E.; Selas, A.; Rubiales, G.; Tesauro, C.; Knudsen, B. K.; Palacios, F. Novel topoisomerase I inhibitors. Syntheses and biological evaluation of phosphorus substituted quinoline derivatives with antiproliferative activity. *Eur. J. Med. Chem.* **2018**, *149*, 225–237. (f) Alonso, C.; Fuertes, M.; González, M.; Rubiales, G.; Tesauro, C.; Knudsen, B. R.; Palacios, F. Synthesis and biological evaluation of indeno[1,5]naphthyridines as topoisomerase I (TopI) inhibitors with antiproliferative activity. *Eur. J. Med. Chem.* **2016**, *115*, 179–190. (g) Tejería, A.; Pérez-Pertejo, Y.; Reguera, R. M.; Balaña-Fouce, R.;

Alonso, C.; Fuertes, M.; González, M.; Rubiales, G.; Palacios, F. Antileishmanial effect of new indeno-1,5-naphthyridines, selective inhibitors of *Leishmania infantum* type IB DNA topoisomerase. *Eur. J. Med. Chem.* **2016**, *124*, 740–749. (h) Alonso, C.; Fuertes, M.; González, M.; Rodríguez-Gascón, A.; Rubiales, G.; Palacios, F. Synthesis and biological evaluation of 1,5-naphthyridines as topoisomerase I inhibitors. A new family of antiproliferative agents. *Curr. Top. Med. Chem.* **2014**, *14*, 2722–2728.

(26) (a) Jadhav, P. D.; Chen, J.-X.; Liu, R.-S. Gold(I)-catalyzed highly enantioselective [4 + 2]-annulations of cyclopentadienes with nitrosoarenes via nitroso-Povarov versus oxidative nitroso-Povarov reactions. *ACS Catal.* **2020**, *10*, 5840–5845. (b) Chen, C.-N.; Liu, R.-S. Gold-catalyzed [4+2] Annulations of Dienes with Nitrosoarenes as 4 π Donors: Nitroso-Povarov Reactions. *Angew. Chem., Int. Ed.* **2019**, *58*, 9831–9835.

(27) Bock, H.; Rudolph, G.; Baltin, E.; Kroner, J. Farbe und Konstitution bei Azoverbindungen. *Angew. Chem.* **1965**, *77*, 469–484.

(28) Smith, C. D.; Gavriluk, J. I.; Lough, A. J.; Batey, R. A. Lewis Acid Catalyzed Three-Component Hetero-Diels–Alder (Povarov) Reaction of N-Arylimines with Strained Norbornene-Derived Dienophiles. *J. Org. Chem.* **2010**, *75*, 702–715.

(29) Alves, M. J.; Azoia, N. G.; Fortes, A. G. Regio- and stereoselective aza-Diels–Alder reaction of ethyl glyoxylate 4-methoxyphenylimine with 1,3-dienes in the presence of BF₃·Et₂O. Evidence for a non-concerted mechanism. *Tetrahedron* **2007**, *63*, 727–734.

(30) Urankar, D.; Steinbücher, M.; Kosjek, J.; Košmrlj, J. N-(Propargyl)diazene-carboxamides for 'click' conjugation and their 1,3-dipolar cycloadditions with azidoalkylamines in the presence of Cu(II). *Tetrahedron* **2010**, *66*, 2602–2613.

(31) Kim, M. H.; Kim, J. Aerobic oxidation of alkyl 2-phenylhydrazinecarboxylates catalyzed by CuCl and DMAP. *J. Org. Chem.* **2018**, *83*, 1673–1679.

(32) Czech, N.; Friese, B.; Umland, F. Asymmetrically substituted diphenylcarbazones as chelate formers. *Anal. Chim. Acta* **1980**, *121*, 275–279.

(33) Zhu, B.; Yang, T.; Gu, Y.; Zhu, S.; Zhu, G.; Chang, J. Enantioselective organocatalytic amination of 2-perfluoroalkyl-oxazol-5(2*H*)-ones towards the synthesis of chiral *N,O*-aminals with perfluoroalkyl and amino groups. *Org. Chem. Front.* **2021**, *8*, 4160–4165.

(34) Zhang, C. Y.; Liu, X. H.; Wang, B. L.; Wang, S. H.; Li, Z. M. Synthesis and antifungal activities of new pyrazole derivatives via 1,3-dipolar cycloaddition reaction. *Chem. Biol. Drug Des.* **2010**, *75*, 489–493.

(35) Zhang, J. Q.; Cao, J.; Li, W.; Li, S. M.; Li, Y. K.; Wang, J. T.; Tang, L. Palladium/copper-catalyzed arylation of alkenes with *N'*-acyl arylhydrazines. *New J. Chem.* **2017**, *41*, 437–441.

(36) Zhang, S.; Li, H.; Yamamoto, Y.; Bao, M. Synthesis of 1*H*-Indole-2,3-dicarboxylates via Rhodium-Catalyzed C-H Annulation of Arylhydrazines with Maleates. *J. Org. Chem.* **2020**, *85*, 12544–12552.